Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

6.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Water release regulating JsSWEET17 transcriptional expression to promote the female flower bud differentiation of Juglans sigillata.

Journal of plant physiology·2026
Same author

AGR2-high cells drive a FOXM1-mediated pro-malignancy program in non-functional pancreatic neuroendocrine tumors (NF-PanNETs) and informatively predict patient outcomes.

Science bulletin·2026
Same author

Immune remodeling of liver metastases: From molecular mechanisms to therapeutic strategies.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

Identifying a better-prognosis pancreatic cancer from its benign inflammatory mimic: a machine learning approach with contrast-enhanced ultrasound for early intervention.

Abdominal radiology (New York)·2026
Same author

Effectiveness and safety of drug-coated balloon in patients with acute ST-segment elevation myocardial infarction during interventional therapy.

Journal of cardiothoracic surgery·2026
Same author

Methods used for smoke evacuation in laparoendoscopic surgery: a technical review.

Surgery today·2025

Related Experiment Video

Updated: Mar 12, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K

TLE1 function and therapeutic potential in cancer.

Da Yuan1, Xue Yang2, Zhenpeng Yuan3

  • 1Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Oncotarget
|November 17, 2016
PubMed
Summary
This summary is machine-generated.

Transducin-like enhancer of split 1 (TLE1) proteins regulate inflammation and cancer. Understanding TLE1

Keywords:
pancreatic cancertransducin-like enhancer of split 1tumor

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

890
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.5K

Related Experiment Videos

Last Updated: Mar 12, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

890
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.5K

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Groucho/Transducin-like enhancer of split (TLE) proteins function as co-repressors in crucial signaling pathways.
  • TLE1 plays a role in negative regulation of inflammation and is implicated in various cancers.
  • TLE1 shows potential as a diagnostic marker and therapeutic target in malignancies.

Purpose of the Study:

  • To elucidate the mechanisms of TLE1 function in cancer initiation and metastasis.
  • To review the role of TLE1 in various cancers.
  • To explore TLE1-targeted approaches for cancer diagnosis and treatment, with a focus on pancreatic cancer.

Main Methods:

  • Literature review of TLE1 functions in cancer.
  • Analysis of TLE1's role in signaling pathways.
  • Exploration of diagnostic and therapeutic strategies targeting TLE1.

Main Results:

  • TLE1 acts as a co-repressor, influencing transcription factors and signaling pathways.
  • TLE1's involvement in inflammation suggests a role in cancer development.
  • Evidence supports TLE1's utility as a biomarker and therapeutic target.

Conclusions:

  • Elucidating TLE1's mechanisms is crucial for cancer research.
  • TLE1 holds promise for targeted cancer therapies and diagnostics.
  • Further investigation into TLE1, especially in pancreatic cancer, is warranted.